GlassScriptPhysician profile
Brian D Callahan
NPI 1932153301
$4,345.18
in general payments reported to CMS, 2019-2025
17 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $959 · 2023: $1,187 · 2024: $949 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.21 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $816.64 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $664.43 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $333.82 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.44 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $275.10 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $247.13 | 2021-2022 | |
| Gilead Sciences, INC. | $207.72 | 2022-2024 | |
| Novo Nordisk INC | $194.10 | 2021-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $115.58 | 2022-2023 | Eliquis, Camzyos |
| Inspire Medical Systems, INC. | $41.18 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $40.58 | 2022 | |
| Neurocrine Biosciences, INC. | $28.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.38 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $20.15 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.35 | 2023 | Veozah |
| Amgen INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.